927
Views
109
CrossRef citations to date
0
Altmetric
Review

Novel biomarkers for prediabetes, diabetes, and associated complications

, , , , , & show all
Pages 345-361 | Published online: 14 Aug 2017

Abstract

The number of individuals with prediabetes is expected to grow substantially and estimated to globally affect 482 million people by 2040. Therefore, effective methods for diagnosing prediabetes will be required to reduce the risk of progressing to diabetes and its complications. The current biomarkers, glycated hemoglobin (HbA1c), fructosamine, and glycated albumin have limitations including moderate sensitivity and specificity and are inaccurate in certain clinical conditions. Therefore, identification of additional biomarkers is being explored recognizing that any single biomarker will also likely have inherent limitations. Therefore, combining several biomarkers may more precisely identify those at high risk for developing prediabetes and subsequent progression to diabetes. This review describes recently identified biomarkers and their potential utility for addressing the burgeoning epidemic of dysglycemic disorders.

Introduction

Prediabetes is defined as an intermediate state with plasma glucose levels ranging between normoglycemia and diabetes. The Centers for Disease Control estimated that in 2012 about 86 million, or one out of three, adults had prediabetes in the US.Citation1 However, 90% of these individuals were unaware of their diagnosis. In 2015, the International Diabetes Federation estimated that the worldwide prevalence of impaired glucose tolerance (IGT) in adults was 318 million and expected to reach 482 million by 2040.Citation2 The annual progression rate to diabetes is 5–10%,Citation3 with older individuals, those with severe insulin resistance (IR), low insulin secretion, and other diabetes risk factors even more likely to progress.Citation4 How can we identify patients with prediabetes and what can we do to prevent progression to diabetes?

Lifestyle and pharmacological interventions have been most effective in preventing progression to diabetes and associated complications. Preservation of β-cell function and reduction in IR and diabetes complications such as retinopathy, cardiovascular disease (CVD), and all-cause mortality were observed subsequent to lifestyle modification.Citation5,Citation6 The Da Qing Diabetes Study in China,Citation6 the Finnish Diabetes Prevention Study,Citation7,Citation8 and the U.S. Diabetes Prevention ProgramCitation3,Citation9 have shown that changes in dietary habits, weight loss, and increased physical activity reduced the risk of progression to diabetes. Bariatric surgery promotes weight loss and is beneficial in prediabetes.Citation10

Identification of risk and diagnosis of prediabetes

Development of prediabetes involves multiple factors including genetics, peripheral IR, defects in insulin secretion, glucotoxicity, lipotoxicity, impaired incretin release, amylin accumulation, inflammation, oxidative stress, and decreased β-cell mass leading to β-cell dysfunction.Citation11Citation13 Prediabetes is classified as isolated impaired fasting glucose (IFG) or IGT.Citation14 Glucose and glycated hemoglobin (HbA1c) criteria for diagnosing dysglycemic states are controversial as there are differing thresholds recommended by the American Diabetes Association (ADA) and the World Health Organization.Citation15,Citation16 We will review several additional biomarkers used to predict the risk of progression to diabetes.

Diagnostic biomarkers and their clinical utility

Hemoglobin A1c

HbA1c is the most commonly used biomarker to diagnose prediabetes and diabetes. HbA1c forms when glucose attaches to the amino-terminal group of the β subunit of hemoglobin.Citation17 HbA1c reflects chronic glycemia rather than glucose levels at a single time point. Currently, the ADA criteria for diabetes are HbA1c ≥6.5% (48 mmol/mol) and 5.7–6.4% (39–46 mmol/mol) for prediabetes.Citation14 Increased HbA1c levels are associated with increased morbidity and mortality. In the Norfolk prospective study, higher HbA1c levels were also associated with increased CVD, cancer, and all-cause mortality.Citation18 Long-term prospective studies, including the Diabetes Control and Complications Trial, the UK Prospective Diabetes Study Group, and the Epidemiology of Diabetes Interventions and Complications study have shown that diabetic complications are directly related to the mean HbA1c, with a level ≥6.5% (48 mmol/mol) associated with retinopathy.Citation19Citation21 Additionally, HbA1c was more strongly correlated with retinopathy than fasting plasma glucose (FPG). Thus, HbA1c may be a better predictor of microvascular complications than FPG.Citation22

HbA1c has several advantages versus FPG and oral glucose tolerance test (OGTT) including greater convenience as fasting is not required, greater pre-analytical stability, and less day-to-day perturbation during periods of stress and illness.Citation23 Since HbA1c reflects chronic exposure to glucose, it is particularly useful for lifestyle modification counseling.Citation23,Citation24 However, there is conflicting evidence regarding the usefulness of HbA1c as it provides moderate sensitivity in diabetes diagnosis when compared to OGTT and FPG ().Citation23,Citation24 OGTT is more strongly correlated with IR and secretion than HbA1c,Citation25 which is expected since the response to a high dose of glucose would more accurately reflect an individual’s physiologic response and insulin secretion and actions. For this reason, HbA1c and OGTT levels may be discrepant as individuals classified as having prediabetes according to OGTT results may be normoglycemic by HbA1c standards.

Table 1 Characteristics of biomarkers for prediabetes, diabetes, and associated complications

Moreover, it is not clear which cut points for HbA1c would be most sensitive. Utilizing ADA criteria, HbA1c may miss individuals with prediabetes despite levels <5.5% (37 mmol/mol).Citation26 The NHANES and Screening for Impaired Glucose Tolerance studies demonstrated that only 60–70% of subjects had normal glucose tolerance (NGT) when HbA1c levels were <5.7% (39 mmol/mol).Citation27Citation29 In addition, the HbA1c threshold for prediabetes does not consider ethnicity, body mass index (BMI), and age, all of which may significantly alter HbA1c levels.Citation30Citation33 For example, HbA1c levels are higher among African Americans, Hispanics, and Asian/Pacific Islanders compared to non-Hispanic whites. One study demonstrated that HbA1c is 0.3% higher in black men and 0.4% higher in black women.Citation34 As a result, standard classification ranges may misdiagnose some individuals from certain ethnic groups with prediabetes, thus overestimating the prevalence of prediabetes.

HbA1c is not always a reliable measurement of average circulating glucose levels. HbA1c has a life span related to the half-life of the red blood cell ranging from 90 to 120 days.Citation35 Therefore, changes in the production rate or circulating life span of red blood cells will affect HbA1c levels; for example, reduced production leads to a greater percent of older cells, whereas more rapid turnover reduces the average time during which the red cells are exposed to hyperglycemia.Citation36 Several clinical conditions may result in overestimation or underestimation of HbA1c levels. Conditions in which HbA1c is falsely elevated include iron deficiency anemia, asplenia, folate and vitamin B-12 deficiency, severe hyper-triglyceridemia, and uremia.Citation36 Falsely low HbA1c occurs in hemolytic anemia, blood loss,Citation37,Citation38 splenomegaly, and end-stage renal disease.Citation36 Hemoglobin variants, such as HbS, HbC, HbD, and HbE,Citation39 may also result in overestimation or under-estimation of HbA1c, depending on which method is used.Citation36 For these reasons, HbA1c alone can be inadequate for diagnosing prediabetes, and more accurate diagnosis may require confirmation with other biomarkers.Citation40

Fructosamine

Fructosamine (FA) has been used as an alternate glycemic marker for diabetes screening and may be potentially useful for diagnosing prediabetes. FA is a ketoamine created by glycosylation of total serum proteins, primarily albumin.Citation41 FA increases in states of high glucose concentrations. Since it reflects average blood glucose concentrations over the previous 1–4 weeks,Citation38 it can be a useful clinical marker of short-term glycemic fluctuation and glucose control.Citation38,Citation52 FA is especially useful in conditions that affect hemoglobin reliability, as already described, and has moderate sensitivity and high specificity ().Citation52 Other advantages of FA include cost-effectiveness and convenience, as its measurement does not require fasting.Citation42,Citation43

Limitations of FA include higher within-subject variability and falsely low levels when conditions leading to rapid albumin turnover are present such as nephrotic syndrome and liver disease.Citation44 There are conflicting data regarding its efficacy as a biomarker for prediabetes. Several studies found that FA correlates with hyperglycemia and HbA1c levels in both type 1 diabetes mellitus and type 2 diabetes mellitus (T2DM).Citation41,Citation45,Citation46 FA may also indicate the risk for developing microvascular complications.Citation45 However, not all studies have found that mean serum FA levels are useful for prediabetes screening.Citation37,Citation38,Citation41,Citation47Citation49

Thus, FA could be a valuable complementary marker in clinical conditions where HbA1c may be inaccurate. However, as the literature concerning FA is limited, and studies included small or niche patient cohorts, there are insufficient data to conclude its role as an alternate biomarker for microvascular complications.

Glycated albumin

Similar to FA, glycated albumin (GA) has been found to be a superior index of glycemic control than HbA1c in patients with renal failure, hemolytic anemia, and those receiving blood transfusions.Citation41,Citation45 FA refers to all glycated serum proteins, which includes GA. Therefore, as FA is not corrected for albumin or total protein concentration, FA levels can fluctuate in certain conditions such as liver disease. Alternatively, GA measures the ratio of GA to total albumin.Citation50 Thus, GA is preferred to FA in clinical conditions that result in protein loss such as nephrotic syndrome, liver, and thyroid disease.Citation50 While it is unclear whether FA should be corrected for total serum protein concentration, one study described an improvement in the correlation of FA with HbA1c when serum FA was corrected for albumin.Citation46,Citation51

Serum GA levels of 15–16% in Asian populations were associated with diabetes.Citation52,Citation53 Furthermore, GA has moderate sensitivity and specificity for diagnosing prediabetes and diabetes (). However, combining FPG <100 mg/dL (5.56 mmol/L) with serum GA <15% to exclude diabetes, and FPG ≥126 mg/dL (7.0 mmol/L) or serum GA ≥17% to diagnose diabetes, increased the sensitivity of GA. There are no clear threshold values for FA and GA for prediabetes but one study used a level ≥230 μmol/L for FA and ≥13.35% for GA, both of which correlated with HbA1c of 5.7% (39 mmol/mol) for detecting prediabetes.Citation49 GA as well as FA is associated with CVD, ischemic stroke, retinopathy, chronic kidney disease, and death in the Atherosclerosis Risk in Communities Study.Citation51,Citation54 These associations were similar to those of HbA1c,Citation54 suggesting that FA and GA may be useful alternative biomarkers in clinical conditions where HbA1c is inaccurate.Citation51 The combination of GA with HbA1c was shown to predict prediabetes with greater sensitivity than HbA1c alone.Citation49 In addition, GA may be superior to FA for detecting prediabetes, whereas the combination of FA with HbA1c was not superior to HbA1c alone.Citation47,Citation49,Citation50,Citation55

There are conditions in which GA may be inaccurate due to changes in albumin turnover. For example, the lower GA levels observed in obesity may be due to increased albumin catabolism and decreased rate of albumin synthesis from obesity-associated inflammation. However, the precise mechanism for the lower GA in obesity is unclear.Citation52,Citation53,Citation56Citation58 GA may be artificially low in individuals with increased BMI, body fat mass, and visceral adiposity.Citation53 The mechanism for alterations in GA levels in these conditions is not well understood.Citation59

1,5 Anhydroglucitol

1,5 Anhydroglucitol (1,5 AG), a dietary monosaccharide, has been suggested as a prediabetes marker. As the proximal tubules in the kidney have a greater affinity for glucose than 1,5 AG, high glucose levels prevent 1,5 AG reabsorption resulting in elevated 1,5 AG urinary excretion. Therefore, plasma 1,5 AG concentrations are inversely correlated with plasma glucose levelsCitation60 demonstrated in a study in which the 1,5 AG level was highest in the control group followed by the prediabetes and diabetes groups, respectively.Citation60 Some studies, but not all, have found an inverse relationship between 1,5 AG and OGTT 2-hour post-glucose levels.Citation61,Citation62 Studies have also shown an inverse relationship between 1,5 AG and HbA1c as well as FPG levels.Citation63

Similar to FA, 1,5 AG may be a useful biomarker as it reflects glucose levels within the preceding 10–14 days.Citation61 1,5 AG is stable, reproducible, and less costly when compared to other glycemic diagnostic tests.Citation61 It may be useful for identifying postprandial glycemic excursions and individuals at risk of complications as 1,5 AG has been associated with retinopathy and microvascular and macrovascular events in diabetes. However, it is unclear if 1,5 AG is superior to HbA1c. Plasma 1,5 AG levels can change based on diet, sex,Citation64,Citation65 and race. Levels are also affected by renal hemodynamics or treatment with sodium-glucose co-transporter 2 inhibitors.Citation66,Citation67 There is no consensus on the use of 1,5 AG as a prediabetes screening tool.Citation65,Citation66

Adiponectin

Adiponectin, derived from adipose tissue, exhibits insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties and is an independent predictor of diabetes.Citation68 Lower levels of adiponectin are associated with increased IR and obesity, while higher levels have been related to lifestyle intervention groups in diabetes prevention trials.Citation68 The association of adiponectin with diabetes risk appears to be evident at a much earlier stage in the progression to diabetes; more specifically, lower adiponectin levels were observed a decade before diabetes was diagnosed, particularly in men.Citation68 Additionally, in offspring of parents with T2DM, baseline adiponectin levels are inversely related to the risk of incident prediabetes independent of ethnic or sex differences.Citation69 Using the hyperinsulinemic euglycemic clamp and intravenous glucose tolerance test, adiponectin levels were directly correlated with insulin sensitivity and indirectly with insulin secretion.Citation69

Fetuin-A

Fetuin-A (FetA) is a hepatic secretory glycoprotein that correlates with increased risk of developing T2DM and associated complications.Citation70 Importantly, unlike adiponectin, the EPIC-Potsdam prospective cohort study found that FetA was independently associated with T2DM after controlling for BMI and waist circumference.Citation70 FetA has been proposed to promote lipid-induced IR through the toll-like receptor 4 (TLR4)-inflammatory signaling pathway, which results in production of inflammatory cytokines.Citation71 As chronic inflammation induced by free fatty acids (FFAs) has been thought to result in IR, the FFA-TLR4 signaling pathway has been recognized as a cause of IR. However, FFA may not bind directly to TLR4. Pal et al showed that FetA binds to TLR4, and regulates insulin sensitivity through this interaction.Citation71 High-fat diet-fed FetA knockdown mice have less TLR4-mediated inflammatory signaling in adipose tissue and IR, whereas intravenous injection of FetA in this model induced inflammatory signaling and IR. FFA-induced inflammatory cytokine expression in adipocytes occurred only in the presence of both FetA and TLR4; removing either prevented FFA-induced IR. FFAs did not produce IR in adipocytes with mutated TLR4 or galactoside-cleaved FetA. FetA, TLR4, interleukin (IL)-6, and tumor necrosis factor (TNF)-α were elevated in obese subjects with diabetes, suggesting an association between lipids, FetA concentrations, and TLR4 expression with IR.

Studies of the association between FetA concentration and CVD have been conflicting. No association,Citation72 a positive association,Citation73 or an inverse association have been reported. However one multi-ethnic US study found a positive trend in those with IFG or diabetes.Citation74 FetA may be associated with higher risk of CVD in those susceptible to the development of IR.Citation74

Taken together, these findings suggest that FetA is an endogenous ligand for TLR4 through which lipids induce IR. FetA may therefore serve as a novel therapeutic target for IR.

Metabolites and microRNA

Amino acids

Felig et al found that fasting branched chain and aromatic amino acids correlated with obesity and serum insulin, whereas glucose loading decreased amino acid levels in insulin-sensitive individuals but not in insulin-resistant individuals.Citation75 This is likely due to insulin-mediated inhibition of proteolysis by skeletal muscle. More recent studies have demonstrated a correlation between amino acids and prediabetes, IR, and obesity.Citation76 Branched chain amino acids (BCAAs), isoleucine, leucine, valine, tyrosine, as well as aromatic amino acid phenylalanine and glycine have been significantly associated with diabetes risk.Citation75,Citation77Citation80 In addition, glutamine, methionine, cysteine, and 2-aminoadipic acid are increased in insulin-resistant states.Citation81Citation83 By contrast, glycine levels are decreased in individuals with prediabetes.Citation84Citation86 To further support this, a comprehensive systematic review and meta-analysis demonstrated positive associations with BCAAs and aromatic amino acids and inverse associations with glycine and glutamine with risk of T2DM.Citation85 Alterations in circulating amino acid levels may represent a significant predictive biomarker for IR and T2DM.

α-Hydroxybutyrate

α-Hydroxybutyrate (α-HB) is an organic acid byproduct produced during the synthesis of α-ketobutyrate (α-KB), a product of amino acid catabolism (threonine and methionine) and glutathione anabolism (cysteine formation pathway) in hepatic tissue.Citation76 The formation of α-KB is catalyzed by lactate dehydrogenase and α-HB. During oxidative stress, the rate of hepatic glutathione synthesis increases, resulting in increased production of α-KB.Citation85,Citation87 This causes a decrease in the availability of L-cysteine for glutathione synthesis and an elevation in α-HB. Thus, in IR, increased oxidative stress and lipid oxidation may cause chronic shifts in glutathione synthesis leading to elevated α-HB levels.Citation88,Citation89 This is demonstrated by increased urinary α-HB excretion in IR.Citation90

Using α-HB as a biomarker, previous studies were able to distinguish NGT-insulin-sensitive (NGT-IS) subjects from IGT and IFG subjects and NGT-IS subjects from those with NGT-IR. Furthermore, using multiple logistic regression analyses, α-HB was found to be significantly associated with IR, independent of sex, age, BMI, and collection site.Citation76 Furthermore, IR was associated with reductions in glycine and serine, which are upstream of α-KB, and an elevation in cysteine. The underlying mechanism may be related to redox imbalance with IR resulting in an increase in α-HB. α-HB may be an effective biomarker for prediabetes.Citation76,Citation89

Linoleoyl-glycerophosphocholine

Choline-containing phospholipids and sphingomyelins have been associated with increased risk of T2DM. Linoleoyl-glycerophosphocholine (L-GPC) was investigated in the Relationship Between Insulin Sensitivity and Cardiovascular Disease study.Citation91 L-GPC is formed by hepatic phospholipase A2 and circulatory lecithin-cholesterol acyltransferase. Phospholipase A2 activity is increased with inflammation. L-GPC may inhibit phospholipase A2 through noncompetitive enzyme inhibition, thereby exhibiting anti-inflammatory properties.Citation76,Citation92 Thus, L-GPC is a negative predictor of T2DM progression in contrast to α-HB, a positive predictor.Citation76,Citation93

Lipoprotein(a)

Lipoprotein(a) [Lp(a)] is synthesized by the liver. Elevated levels of LP(a) are an independent risk factor for developing CVD.Citation94 An inverse relationship between serum Lp(a) and the prevalence of prediabetes and T2DM has been reported, although the mechanism for the relationship between serum Lp(a) and T2DM is not clear.Citation95 Insulin may play a role in reducing Lp(a) levels.Citation95

Triglycerides and high-density lipoprotein

Elevated serum triglyceride (Tg) levels have been associated with β-cell dysfunction and reduced insulin secretion in prediabetes.Citation94 Mechanistically, hypertriglyceridemia reduces glucose-induced insulin secretion through the glucose-fatty acid cycle, and promotes β-cell apoptosis by stimulating the production of ceramide and nitric oxide.Citation96 Also, elevated Tg levels can cause lipotoxicity by accumulating within pancreatic β cells.Citation94,Citation96

Cholesteryl ester transfer protein mediates the exchange of lipids from Tg-rich lipoproteins with high-density lipoprotein (HDL). Increased Tg levels in insulin-resistant states accelerate this exchange.Citation97 Then, the Tg in HDL cholesterol (HDL-C) are hydrolyzed by hepatic lipase, resulting in smaller HDL-C particles. ATP-binding cassette transporter A (ABCA1) mediates the efflux of cholesterol to small HDL3 particles.Citation97 Subjects with prediabetes have significantly increased levels of small HDL3 particles compared with HDL-C levels.Citation97 The proportion of small HDL3 particles is positively associated with Tg and negatively associated with HDL-C.Citation97 In contrast to Tg, HDL-C promotes insulin secretion through its interaction with ABCA1. Low HDL-C concentrations may also lead to progression to diabetes from prediabetes. However, it is unclear if HDL-C levels are associated with β-cell dysfunction.Citation96

Lipoprotein-associated phospholipase A2 (LpPLA2) is an enzyme that degrades oxidatively fragmented phospholipids and may play a role in atherogenesis.Citation97 Individuals with IFG have significantly decreased HDL-associated LpPLA2 (HDL-LpPLA2) activity compared with subjects with normoglycemia. Low-density lipoprotein-associated LpPLA2 may exert pro-inflammatory effects, whereas HDL-LpPLA2 may have an atheroprotective role.Citation97 Increased levels of small HDL3 particles and decreased activity of the anti-atherogenic HDL-LpPLA2 were found in subjects with IFG.Citation97 Thus, subclasses of HDL-C may play a role in the pathogenesis of prediabetes.

Ceramide

In addition to Tg, ceramides have a positive association with prediabetes and T2DM.Citation85,Citation98 Ceramides are lipid molecules that mediate IR.Citation99,Citation100 Studies have shown that ceramides inhibit insulin action by decreasing phosphorylation and activation of Akt; accumulate in insulin-resistant tissues; and induce inflammation through the nuclear factor-κB (NF-Kβ)–TNF-α axis.Citation100,Citation101 Furthermore, ceramides correlate with coronary artery disease.Citation102

Additional studies are needed to understand the relationships between lipid metabolism, prediabetes, and diabetes.

Ferritin and transferrin

Ferritin is an intracellular protein that stores and releases iron. Elevated serum ferritin and transferrin saturation have been strongly associated with increased risk of prediabetes and diabetes.Citation103,Citation104 Furthermore, a positive correlation with increased FPG and serum ferritin has been demonstrated.Citation104 Iron contributes to IR through the production of highly active radical formation, damage to DNA and cell membrane integrity, β-cell oxidative stress resulting in decreased insulin secretory capacity,Citation105 and interference with glucose uptake in skeletal muscles and adipocytes. Moreover, catalytic iron stimulates the formation of reactive oxidative species, hepatic dysfunction, and β-cell apoptosis,Citation105,Citation106 all of which contribute to IR. Dietary iron restriction or chelation prevents the development of diabetes and loss of β-cell function.Citation105 The threshold levels of ferritin that correlate with IR are uncertain as these may vary with sex and age.Citation107 Additional studies are needed to better understand ferritin and its role in prediabetes.

Mannose binding lectin serine peptidase, thrombospondin 1, and glycosylphosphatidylinositol-specific phospholipase D1

Mannose binding lectin-associated serine proteases are important for innate immune responses and activation of the lectin pathway of the complement system.Citation108 MASP1, the most abundant serine protease of the complement lectin pathway, has a major role in the complement cascade.Citation108 MASP1 has been shown to positively correlate with prediabetes, diabetes, as well as CVD. One study demonstrated that the onset of prediabetes and IR occurred earlier in those with increased MASP1 plasma levels.Citation109 There was a positive association with elevated FPG and 2-hour glucose levels, but this weakened when adjusted for triacylglycerol levels. This suggests that triacylglycerol may mediate part of the association between MASP1 and HOMA-IR.Citation109

Thrombospondin 1 (THBS1) and glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) are positively associated with prediabetes, whereas apolipoprotein A-IV (ApoA-IV) is inversely associated.Citation109 THBS1 is a glycoprotein and member of the THB family, which has numerous functions such as cellular adhesion and migration regulation, cytoskeletal organization, cell proliferation and apoptosis, and cell-to-cell interactions.Citation110 This matrix protein has been found to be associated with increased IR, which may be attributable to THB’s inflammatory properties, as well as increased 2-hour glucose levels and higher prediabetes prevalence.Citation109

GPLD1, mainly produced in the liver, releases glycosylphosphatidylinositol-anchored membrane proteins.Citation111 It is associated with serum lipoproteins and has been linked with diabetes and prediabetes.Citation109,Citation111 ApoA-IV, a component of chylomicrons, very low-density lipoprotein and HDL, has been shown to have a significant inverse relationship with prediabetes and diabetes.Citation109 The exact role of ApoA-IV in vivo is unknown aside from regulating appetite and chylomicron production but it may have antioxidant and anti-inflammatory properties.Citation112,Citation113

There are limited studies describing the relationship between THBS1, GPLD1, and ApoA-IV and prediabetes; therefore, more data are required to better understand their respective roles.

Acyl-carnitine

Fatty acid oxidation (FAO) is a major source of cellular energy.Citation114 L-carnitine plays a significant role in FAO as it transports activated long chain fatty acids (LCFA) from the cytosol into the mitochondria, a process referred to as the carnitine shuttle. Once inside, fatty acids undergo esterification to CoA. Carnitine palmitoyltransferase 1 exchanges the CoA moiety for carnitine resulting in acyl-carnitine production.Citation115 Recently, serum levels of acyl-carnitines have been shown to be elevated in prediabetes.Citation116,Citation117 However, the essential role of acyl-carnitine in FAO and its mechanism in IR are uncertain. It has been proposed that impairment of FAO and dysregulated mitochondrial function result in accumulation of intermediary products such as acyl-carnitines. Thus, there is a mismatch of LCFA delivery and the tricarboxylic acid cycle.Citation118 Furthermore, acyl-carnitines interact with NF-Kβ, which promotes inflammation and IR.Citation118 However, there are few studies of acyl-carnitines in prediabetes.

MicroRNAs

MicroRNAs (miRNAs) are small, noncoding RNAs involved in post-transcriptional gene expression. These are pertinent to many biological and pathophysiological processes such as growth, development, differentiation, proliferation, and cell death. Recently, miRNAs have been studied in pre-diabetes,Citation119Citation121 several of which were increased including miR-192 and miR-193b. miR-192 regulates tumor protein p53, and miR-193b is important for the differentiation of brown adipocytes and inflammation reduction.Citation122 Levels of both miRNAs were elevated in those with IFG and IGT. Furthermore, miR-192 and miR-193b have been correlated with Tg levels and the fatty liver index in animal models,Citation120 which may be significant as a fatty liver can be associated with prediabetes.Citation123 Moreover, exercise was shown to significantly decrease miR-192 and miR-193b concentrations.Citation120

Other miRNAs significantly elevated in T2DM include miR-9, miR-29a, miR-30d, miR-34a, miR-124a2, miR-146a, and miR-375, all thought to play a role in β-cell function. These miRNAs were found to negatively regulate insulin expression, production, or secretion. However, no statistically significant increases were found in subjects with prediabetes, suggesting that there may be reversible pathophysiological processes that occur during prediabetes but not in T2DM.Citation124

Additional miRNAs are decreased in prediabetes. Circulating levels of miR-126, abundant in endothelial cells playing a role in endothelial homeostasis and vascular integrity, are decreased in IGT/IFG and T2DM.Citation125 miR-126 levels are increased with diet and exercise. miRNA-15a levels were also significantly lower in prediabetes, T2DM, and IFG/IGT.Citation119 miR-15a is thought to regulate and promote insulin biosynthesis by inhibiting endogenous uncoupling protein-2 gene expression and increasing insulin secretion.Citation126 Therefore, miR-15a has been suggested to play a significant role in β-cell function and insulin synthesis.

Inflammatory markers

Prediabetes and IR are characterized by a marked inflammatory state.Citation127Citation129 Biochemical markers of acute-phase reactants and inflammatory cytokines are elevated on the onset of T2DM and may even further increase with disease progression. These markers, such as C-reactive protein (CRP), white blood cell count, and fibrinogen, have been investigated as potential predictors for the development of T2DM such as in the Atherosclerosis Risk in Communities study.Citation130

CRP and IL-6

CRP is the most widely studied inflammatory marker in CVD and its clinical use continues to evolve. CRP is primarily derived from IL-6-dependent hepatic biosynthesis and is a primary marker of the acute phase response. Many investigations have demonstrated elevated levels of both IL-6 and CRP among individuals with T2DM and IR. In the Women’s Health Study, a nationwide cohort of 27,628 women without diabetes mellitus (DM), CVD, or cancer at baseline, 188 women developed DM over a 4-year follow-up period.Citation131 Median baseline levels of IL-6 and CRP were significantly higher among cases than controls. In addition, higher levels of IL-6 and CRP were associated with a greater risk of diabetes development. Relative risks of incident T2DM for increasing quartiles of IL-6 were 1.0, 2.5, 4.1, and 7.5, respectively (p<0.001 for trend), and for increasing quartiles of CRP were 1.0, 2.2, 8.7, and 15.7, respectively (p<0.001 for trend). While adjustment for BMI attenuated these relative risks, the results were still positive. These findings were similar when only including women with a baseline HbA1c of 6.0% (42 mmol/mol) or less and after adjustment for fasting insulin levels. This suggests that these inflammatory markers may be useful in identifying individuals at risk of developing T2DM.

The Insulin Resistance Atherosclerosis Study (IRAS) was a multicenter study of 1,625 individuals followed over 5.2 years.Citation132 Individuals with prediabetes were defined as those developing diabetes during follow-up. Subjects with prediabetes who were also insulin resistant had elevated CRP levels compared to both insulin-sensitive individuals with prediabetes and non-diabetics. These differences were thought partly due to differences in body weight. Since subjects with prediabetes and IR were not hyperglycemic, subclinical inflammation could not be attributed solely to hyperglycemia. This hypothesis was supported in another study demonstrating that the glycemic index was not associated with CRP and risk of T2DM, suggesting that hyperglycemia per se is not the underlying mechanism linking diabetes and inflammation.Citation133

The association between CRP and prediabetes has been confirmed in other studies. The Gutenberg Health Study was a prospective, observational single-center cohort study that included 15,010 adults, 1,425 of whom had prediabetes and 1,299 had diabetes according to HbA1c concentrations.Citation134 CRP was shown to increase incrementally from normoglycemia to prediabetes (1.4 vs. 2.3 mg/L), whereas only a small increase was observed between subjects with prediabetes and diabetes (2.3 vs. 2.4 mg/L), suggesting that early immune activation plays a role in the onset of diabetes. Genetic variants in the innate immune system and inflammatory cascade also affect CRP and predisposition to T2DM.Citation128,Citation135

Other studies have further supported the association between increased levels of CRP and IL-6 and prediabetes.Citation127,Citation136 In a meta-analysis evaluating IL-6 with the risk for developing T2DM, the overall relative risk was 1.31 (95% confidence interval [CI] 1.17–1.46; p=0.000) per 1 log pg/mL increment in IL-6 levels.Citation137 In another meta-analysis, these authors found that the overall risk of T2DM was 1.26 (95% CI 1.16–1.37; p=0.000) per 1 log mg/L increment in CRP levels.Citation137 There may be differences in CRP as a predictor of diabetes in women compared to men.Citation137 Interestingly, the meta-analysis showed that IL-6 was more strongly associated with T2DM than CRP, questioning the pathogenesis of subclinical inflammation in diabetes. CRP may therefore have a potential downstream role in this process but may not be the precipitating factor. However, in contrast to the latter findings, another study demonstrated that CRP was elevated in obesity and IR, whereas levels were low in insulin-sensitive or obese individuals.Citation138

White blood cell count, fibrinogen, and hematological indices

White blood cell count and fibrinogen are also markers of immunity and inflammation that may have clinical relevance for disease progression and organ-specific complications in diabetes. Leukocytosis may also predict coronary heart disease.Citation139 Therefore, the early identification of high-risk individuals may prevent the onset and/or progression of CVD. A high white blood cell count has been shown to predict worsening insulin action, insulin secretory function, and T2DM development in Pima Indians.Citation140 Fibrinogen may contribute to atherosclerosis by affecting blood viscosity, platelet aggregation, and fibrin formation. Fibrinogen also modulates coagulation activation and fibrinolysis, and may enhance plaque progression. In the Gutenberg Health Study, fibrinogen levels were higher in prediabetes than in diabetes, although the reason for this finding is not clear.Citation134

The neutrophil-lymphocyte ratio (NLR) and plateletlymphocyte ratio (PLR) are also indicators of subclinical inflammation. In a study of 110 adults, subjects were divided into four groups: NGT, IGT, newly diagnosed T2DM, and known T2DM without complications. NLR values were significantly higher in those with prediabetes, newly diagnosed diabetes, and known diabetes compared to the control group.Citation141 PLR values were significantly lower in the prediabetes and newly diagnosed diabetes groups but higher in subjects with T2DM. Of note, NLR was higher in obese patients with diabetes than in those without diabetes. NLR has also been associated with both microvascular and macrovascular complications in diabetes.Citation141Citation144

Another investigation demonstrated that 1-hour post-load glucose levels were associated with a significantly higher white blood cell count and fibrinogen.Citation145 Fiorentino et al showed that individuals with prediabetes had a significant increase in CRP, fibrinogen, and white blood cell count after adjusting for sex, age, smoking, and fasting and 1- and 2-hour post-load glucose levels.Citation146

Plasminogen activator inhibitor-1

Tissue plasminogen activator-1 (PAI-1) is a marker of reduced fibrinolysis with decreased activity resulting in coagulation abnormalities.Citation147 Changes in PAI-1 levels were shown to be an independent predictor of incident diabetes in IRAS.Citation148

IL-18

Through oxidative mechanisms, hyperglycemia acutely increases cytokine concentrations including plasma IL-6, as already described, as well as TNF-α and IL-18.Citation149 In a prospective case-cohort study, subjects with IL-18 in the highest quartile had a 70% increased risk of developing T2DM compared to those in the lowest quartile.Citation149 IL-18 also increased with progression from prediabetes to diabetes in the Gutenberg study.Citation134

IL-1 receptor antagonist

The IL-1 pathway may be induced by glucose and FFAs in the setting of overfeeding and contribute to an inflammatory state.Citation150 The IL-1 receptor antagonist (IL-1RA), produced by adipocytes, is an anti-inflammatory marker elevated in prediabetes and diabetes, possibly as a reactive response to inflammation.Citation134 In the Whitehall Study, a case-cohort study of 355 individuals with incident T2DM, an increase in IL-1RA in individuals with prediabetes occurred in parallel with decreasing insulin sensitivity, transiently increasing β-cell function, and 2-hour glucose levels, all of which occurred years before the occurrence of T2DM.Citation151 Levels of IL-1RA were elevated 13 years before the diagnosis of T2DM. Of note, IL-1RA increased rapidly 6 years before diagnosis even after adjusting for obesity.

Patient-focused perspectives

According to the Centers for Disease Control and Prevention, as many as 90% of individuals with prediabetes are undiagnosedCitation1 and therefore fail to receive guidance on lifestyle changes to prevent progression to T2DM. While HbA1c and glucose determinations for screening have been used in clinical practice for many years, each has deficiencies. As previously discussed, since HbA1c is insensitive for diagnosing acute and intermittent hyperglycemia and can be affected by various medical conditions and ethnicity, identification of other biomarkers would be of immense value. OGTT, while providing important information with regard to risk of developing T2DM that HbA1c or FPG do not, is associated with considerable variability, requires fasting, and is invasive and time consuming. However, intermediate time points during the OGTT (e.g., 30 or 60 minute post-load values) appear to predict progression to T2DM better than fasting, 2-hour post-load glucose or HbA1c levels, making this approach more favorable with the possibility of shortening the traditional 2-hour test.Citation152 Additional studies are required to identify the most accurate biomarker(s), recognizing that a single determinant will likely have inherent limitations. Therefore, combining several biomarkers may more precisely predict those at high risk for developing prediabetes and subsequent progression to diabetes.

Conclusion and future perspectives

Categorical or absolute definitions of dysglycemia when applied to a continuous pathophysiologic process may inadvertently underestimate those at risk for progression. Progressively rising glucose levels, even within the so-called “normal range”, occur relatively late in the evolution to T2DM when β-cell function may already be reduced.Citation153 Therefore, a vital need exists to identify more sensitive and precise biomarkers capable of predicting progression to dysglycemic states at the earliest time point when β-cell function is still relatively more optimal and may be more responsive to lifestyle modification. Combining biomarkers in a clinical setting may provide better sensitivity and specificity in predicting prediabetes and diabetes. Additional comparison studies of biomarkers will be required to ascertain their clinical utility. Furthermore, genetic studies assessing mutations may provide additional insight into associations with metabolic abnormalities.Citation153,Citation154

Disclosure

The authors report no conflicts of interest in this work.

References

  • Centers for Disease Control National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States Atlanta, GA U.S. Department of Health and Human Services 2014
  • International Diabetes Federation IDF Diabetes Atlas 7th ed Brussels, Belgium International Diabetes Federation 2015
  • Bansal N Prediabetes diagnosis and treatment: a review World J Diabetes 2015 6 2 296 303 25789110
  • Kahn SE The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes Diabetologia 2003 46 1 3 19 12637977
  • Gong Q Gregg EW Wang J Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study Diabetologia 2011 54 2 300 307 21046360
  • Li G Zhang P Wang J Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study Lancet Diabetes Endocrinol 2014 2 6 474 480 24731674
  • Tuomilehto J Lindström J Eriksson JG Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 2001 344 18 1343 1350 11333990
  • Lindström J Louheranta A Mannelin M Finnish Diabetes Prevention Study Group The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity Diabetes Care 2003 26 12 3230 3236 14633807
  • Diabetes Prevention Program Research Group Knowler WC Fowler SE Hamman RF 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 2009 374 9702 1677 1686 19878986
  • Sjöström CD Lissner L Wedel H Sjöström L Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study Obes Res 1999 7 5 477 484 10509605
  • Abdul-Ghani MA Tripathy D DeFronzo RA Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose Diabetes Care 2006 29 5 1130 1139 16644654
  • Abdul-Ghani MA Jenkinson CP Richardson DK Tripathy D DeFronzo RA Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study Diabetes 2006 55 5 1430 1435 16644701
  • Festa A D’Agostino RJr Hanley AJ Karter AJ Saad MF Haffner SM Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose Diabetes 2004 53 6 1549 1555 15161760
  • American Diabetes Association Standards of medical care in diabetes—2014 Diabetes Care 2014 37 Suppl 1 S14 S80 24357209
  • American Diabetes Association (2). Classification and diagnosis of diabetes Diabetes Care 2015 38 Suppl 1 S8 S16
  • World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia 2006 Geneva World Health Organization 2013
  • Bookchin RM Gallop PM Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group Biochem Biophys Res Commun 1968 32 1 86 93 4874776
  • Pfister R Sharp SJ Luben R Khaw KT Wareham NJ No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population Diabetologia 2011 54 8 2025 2032 21584793
  • White NH Sun W Cleary PA DCCT-EDIC Research Group Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents Diabetes 2010 59 5 1244 1253 20150283
  • Diabetes Control and Complications Trial Research Group Nathan DM Genuth S Lachin J The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
  • Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
  • Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 1997 20 7 1183 1197 9203460
  • Bonora E Tuomilehto J The pros and cons of diagnosing diabetes with A1C Diabetes Care 2011 34 Suppl 2 S184 S190 21525453
  • Olson DE Rhee MK Herrick K Ziemer DC Twombly JG Phillips LS Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria Diabetes Care 2010 33 10 2184 2189 20639452
  • Lorenzo C Wagenknecht LE Hanley AJ Rewers MJ Karter AJ Haffner SM A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS) Diabetes Care 2010 33 9 2104 2109 20573754
  • Zhou X Pang Z Gao W Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China Diabetes Care 2010 33 3 545 550 20007941
  • James C Bullard KM Rolka DB Implications of alternative definitions of prediabetes for prevalence in U.S. adults Diabetes Care 2011 34 2 387 391 21270196
  • Guo F Moellering DR Garvey WT Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age Metab Syndr Relat Disord 2014 12 5 258 268 24512556
  • Malkani S Mordes JP Implications of using hemoglobin A1C for diagnosing diabetes mellitus Am J Med 2011 124 5 395 401 21531226
  • Christensen DL Witte DR Kaduka L Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups Diabetes Care 2010 33 3 580 582 20009099
  • Herman WH Ma Y Uwaifo G Diabetes Prevention Program Research Group Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program Diabetes Care 2007 30 10 2453 2457 17536077
  • Li J Ma H Na L Increased hemoglobin A1c threshold for pre-diabetes remarkably improving the agreement between A1c and oral glucose tolerance test criteria in obese population J Clin Endocrinol Metab 2015 100 5 1997 2005 25751104
  • Pani LN Korenda L Meigs JB Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004 Diabetes Care 2008 31 10 1991 1996 18628569
  • Herman WH Do race and ethnicity impact hemoglobin A1c independent of glycemia? J Diabetes Sci Technol 2009 3 4 656 660 20144308
  • Sacks DB Bruns DE Goldstein DE Maclaren NK McDonald JM Parrott M Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus Clin Chem 2002 48 3 436 472 11861436
  • Radin MS Pitfalls in hemoglobin A1c measurement: when results may be misleading J Gen Intern Med 2014 29 2 388 394 24002631
  • Lee JE Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol Ann Pediatr Endocrinol Metab 2015 20 2 74 78 26191510
  • Malmström H Walldius G Grill V Jungner I Gudbjörnsdottir S Hammar N Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies–cross-sectional and longitudinal experience from the AMORIS cohort PLoS One 2014 9 10 e111463 25353659
  • Bry L Chen PC Sacks DB Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin Clin Chem 2001 47 2 153 163 11159762
  • Sacks DB Arnold M Bakris GL Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus Clin Chem 2011 57 6 e1 e47 21617152
  • Ribeiro RT Macedo MP Raposo JF HbA1c, fructosamine, and glycated albumin in the detection of dysglycaemic conditions Curr Diabetes Rev 2016 12 1 14 19 26126638
  • Austin GE Wheaton R Nanes MS Rubin J Mullins RE Usefulness of fructosamine for monitoring outpatients with diabetes Am J Med Sci 1999 318 5 316 323 10555094
  • Weerasekera DS Peiris H The value of serum fructosamine in comparison with oral glucose tolerance test (OGTT) as a screening test for detection of gestational diabetes mellitus J Obstet Gynaecol 2000 20 2 136 138 15512500
  • Schleicher ED Olgemöller B Wiedenmann E Gerbitz KD Specific glycation of albumin depends on its half-life Clin Chem 1993 39 4 625 628 8472356
  • Selvin E Francis LM Ballantyne CM Nontraditional markers of glycemia: associations with microvascular conditions Diabetes Care 2011 34 4 960 967 21335368
  • Rodríguez-Segade S Rodríguez J Camiña F Corrected Fructosamine improves both correlation with HbA1C and diagnostic performance Clin Biochem 2017 50 3 110 115 27777100
  • Chan CL Pyle L Kelsey M Newnes L Zeitler PS Nadeau KJ Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia – 1,5-anhydroglucitol, fructosamine, and glycated albumin Pediatr Diabetes 2016 17 3 206 211 25652226
  • Malkan UY Gunes G Corakci A Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers Springerplus 2015 4 587 26543722
  • Sumner AE Duong MT Aldana PC A1C combined with glycated albumin improves detection of prediabetes in Africans: the Africans in America Study Diabetes Care 2016 39 2 271 277 26681716
  • Danese E Montagnana M Nouvenne A Lippi G Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes J Diabetes Sci Technol 2015 9 2 169 176 25591856
  • Selvin E Rawlings AM Grams M Prognostic utility of fructosamine and glycated albumin for incident diabetes and microvascular complications Lancet Diabetes Endocrinol 2014 2 4 279 288 24703046
  • Wu WC Ma WY Wei JN Serum glycated albumin to guide the diagnosis of diabetes mellitus PLoS One 2016 11 1 e0146780 26765575
  • Furusyo N Koga T Ai M Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS) Diabetologia 2011 54 12 3028 3036 21947435
  • Selvin E Rawlings AM Lutsey PL Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death Circulation 2015 132 4 269 277 26022911
  • Shima K Abe F Chikakiyo H Ito N The relative value of glycated albumin, hemoglobin A1c and fructosamine when screening for diabetes mellitus Diabetes Res Clin Pract 1989 7 4 243 250 2612342
  • Okada T Nakao T Matsumoto H Yamanaka T Nagaoka Y Tamekuni T Influence of age and nutritional status on glycated albumin values in hemodialysis patients Intern Med 2009 48 17 1495 1499 19721292
  • Bulló M García-Lorda P Megias I Salas-Salvadó J Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression Obesity Res 2003 11 4 525 531
  • Koga M Hirata T Kasayama S Ishizaka Y Yamakado M Body mass index negatively regulates glycated albumin through insulin secretion in patients with type 2 diabetes mellitus Clin Chim Acta 2015 438 19 23 25102071
  • Ma XJ Pan JM Bao YQ Combined assessment of glycated albumin and fasting plasma glucose improves the detection of diabetes in Chinese subjects Clin Exp Pharmacol Physiol 2010 37 10 974 979 20557319
  • Buse JB Freeman JL Edelman SV Jovanovic L McGill JB Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker Diabetes Technol Ther 2003 5 3 355 363 12828817
  • Yamanouchi T Akanuma Y Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control Diabetes Res Clin Pract 1994 24 Suppl S261 S268 7859616
  • Yamanouchi T Akanuma H Nakamura T Akaoka I Akanuma Y Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients Diabetologia 1988 31 1 41 45 3350220
  • Yamanouchi T Minoda S Yabuuchi M Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients Diabetes 1989 38 6 723 729 2656341
  • Wang Y Yuan Y Zhang Y Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes Acta Diabetol 2017 54 5 425 431 27896445
  • Kim WJ Park CY 1,5-Anhydroglucitol in diabetes mellitus Endocrine 2013 43 1 33 40 22847316
  • Balis DA Tong C Meininger G Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol J Diabetes 2014 6 4 378 380 24330128
  • Hasslacher C Kulozik F Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I–III: a comparative study with HbA1c and glycated albumin J Diabetes 2016 8 5 712 719 26615054
  • Tabák AG Carstensen M Witte DR Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study Diabetes Care 2012 35 12 2540 2547 22933430
  • Jiang Y Owei I Wan J Ebenibo S Dagogo-Jack S Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study BMJ Open Diabetes Res Care 2016 4 1 e000194
  • Stefan N Sun Q Fritsche A Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies PLoS One 2014 9 3 e92238 24643166
  • Pal D Dasgupta S Kundu R Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance Nat Med 2012 18 8 1279 1285 22842477
  • Sun Q Jiménez MC Townsend MK Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses’ Health Study J Am Heart Assoc 2014 3 3 e000939 24963103
  • Weikert C Stefan N Schulze MB Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke Circulation 2008 118 24 2555 2562 19029462
  • Aroner SA St-Jules DE Mukamal KJ Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis Atherosclerosis 2016 248 224 229 27038419
  • Felig P Marliss E Cahill GFJr Plasma amino acid levels and insulin secretion in obesity N Engl J Med 1969 281 15 811 816 5809519
  • Gall WE Beebe K Lawton KA RISC Study Group alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population PLoS One 2010 5 5 e10883 20526369
  • Newgard CB An J Bain JR A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance Cell Metab 2009 9 4 311 326 19356713
  • Huffman KM Shah SH Stevens RD Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women Diabetes Care 2009 32 9 1678 1683 19502541
  • Chen T Ni Y Ma X Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations Sci Rep 2016 6 20594 26846565
  • Knebel B Strassburger K Szendroedi J German Diabetes Study Group Specific metabolic profiles and their relationship to insulin resistance in recent-onset type 1 and type 2 diabetes J Clin Endocrinol Metab 2016 101 5 2130 2140 26829444
  • Wang TJ Ngo D Psychogios N 2-Aminoadipic acid is a biomarker for diabetes risk J Clin Invest 2013 123 10 4309 4317 24091325
  • Wang TJ Larson MG Vasan RS Metabolite profiles and the risk of developing diabetes Nat Med 2011 17 4 448 453 21423183
  • El-Khairy L Ueland PM Nygård O Refsum H Vollset SE Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine Study Am J Clin Nutr 1999 70 6 1016 1024 10584046
  • Wang-Sattler R Yu Z Herder C Novel biomarkers for pre-diabetes identified by metabolomics Mol Syst Biol 2012 8 615 23010998
  • Guasch-Ferré M Hruby A Toledo E Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis Diabetes Care 2016 39 5 833 846 27208380
  • Sekhar RV McKay SV Patel SG Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine Diabetes Care 2011 34 1 162 167 20929994
  • Fiehn O Garvey WT Newman JW Lok KH Hoppel CL Adams SH Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women PLoS One 2010 5 12 e15234 21170321
  • Landaas S The formation of 2-hydroxybutyric acid in experimental animals Clin Chim Acta 1975 58 1 23 32 164303
  • Rosalki SB Wilkinson JH Reduction of alpha-ketobutyrate by human serum Nature 1960 188 1110 1111 13743238
  • Lord RS Bralley JA Clinical applications of urinary organic acids. Part I: Detoxification markers Altern Med Rev 2008 13 3 205 215 18950247
  • Cobb J Eckhart A Motsinger-Reif A Carr B Groop L Ferrannini E α-Hydroxybutyric acid is a selective metabolite biomarker of impaired glucose tolerance Diabetes Care 2016 39 6 988 995 27208342
  • Cunningham TJ Yao L Lucena A Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines’ unexpected therapeutic properties J Inflamm (Lond) 2008 5 17 18945345
  • Cobb J Gall W Adam KP A novel fasting blood test for insulin resistance and prediabetes J Diabetes Sci Technol 2013 7 1 100 110 23439165
  • Dotevall A Johansson S Wilhelmsen L Rosengren A Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA study Diabet Med 2004 21 6 615 622 15154949
  • Ding L Song A Dai M Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population J Lipid Res 2015 56 4 920 926 25649924
  • Shimodaira M Niwa T Nakajima K Kobayashi M Hanyu N Nakayama T Serum triglyceride levels correlated with the rate of change in insulin secretion over two years in prediabetic subjects Ann Nutr Metab 2014 64 1 38 43 24732283
  • Filippatos TD Rizos EC Tsimihodimos V Gazi IF Tselepis AD Elisaf MS Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A2 in subjects with prediabetes Lipids 2013 48 6 547 555 23546765
  • Meikle PJ Wong G Barlow CK Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes PLoS One 2013 8 9 e74341 24086336
  • Haus JM Kashyap SR Kasumov T Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance Diabetes 2009 58 2 337 343 19008343
  • Summers SA Ceramides in insulin resistance and lipotoxicity Prog Lipid Res 2006 45 1 42 72 16445986
  • Holland WL Summers SA Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism Endocr Rev 2008 29 4 381 402 18451260
  • Jiang XC Paultre F Pearson TA Plasma sphingomyelin level as a risk factor for coronary artery disease Arterioscler Thromb Vasc Biol 2000 20 12 2614 2618 11116061
  • Aregbesola A Virtanen JK Voutilainen S Serum ferritin and glucose homeostasis: change in the association by glycaemic state Diabetes Metab Res Rev 2015 31 5 507 514 25470760
  • Sharifi F Nasab NM Zadeh HJ Elevated serum ferritin concentrations in prediabetic subjects Diab Vasc Dis Res 2008 5 1 15 18 18398807
  • Cooksey RC Jones D Gabrielsen S Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep−/−) mouse Am J Physiol Endocrinol Metab 2010 298 6 E1236 E1243 20354157
  • Huang J Jones D Luo B Iron overload and diabetes risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis Diabetes 2011 60 1 80 87 20876715
  • Zacharski LR Ornstein DL Woloshin S Schwartz LM Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data Am Heart J 2000 140 1 98 104 10874269
  • Dobó J Schroeder V Jenny L Cervenak L Závodszky P Gál P Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation Mol Immunol 2014 61 2 69 78 24935208
  • von Toerne C Huth C de Las Heras Gala T MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study Diabetologia 2016 59 9 1882 1892 27344311
  • Lawler J The functions of thrombospondin-1 and-2 Curr Opin Cell Biol 2000 12 5 634 640 10978901
  • Hoener MC Brodbeck U Phosphatidylinositol-glycan-specific phospholipase D is an amphiphilic glycoprotein that in serum is associated with high-density lipoproteins Eur J Biochem 1992 206 3 747 757 1606959
  • Wang F Kohan AB Lo CM Liu M Howles P Tso P Apolipoprotein A-IV: a protein intimately involved in metabolism J Lipid Res 2015 56 8 1403 1418 25640749
  • Green PH Glickman RM Riley JW Quinet E Human apolipoprotein A-IV: Intestinal origin and distribution in plasma J Clin Invest 1980 65 4 911 919 6987270
  • Eaton S Control of mitochondrial beta-oxidation flux Prog Lipid Res 2002 41 3 197 239 11814524
  • Ramsay RR Gandour RD van der Leij FR Molecular enzymology of carnitine transfer and transport Biochim Biophys Acta 2001 1546 1 21 43 11257506
  • Zhang X Zhang C Chen L Han X Ji L Human serum acylcarnitine profiles in different glucose tolerance states Diabetes Res Clin Pract 2014 104 3 376 382 24837145
  • Mai M Tönjes A Kovacs P Stumvoll M Fiedler GM Leichtle AB Serum levels of acylcarnitines are altered in prediabetic conditions PLoS One 2013 8 12 e82459 24358186
  • Adams SH Hoppel CL Lok KH Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women J Nutr 2009 139 6 1073 1081 19369366
  • Al-Kafaji G Al-Mahroos G Alsayed NA Hasan ZA Nawaz S Bakhiet M Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes Mol Med Rep 2015 12 5 7485 7490 26460159
  • Párrizas M Brugnara L Esteban Y Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention J Clin Endocrinol Metab 2015 100 3 E407 E415 25532038
  • Yang Z Chen H Si H Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes Acta Diabetol 2014 51 5 823 831 24981880
  • Sun L Xie H Mori MA Mir193b-365 is essential for brown fat differentiation Nat Cell Biol 2011 13 8 958 965 21743466
  • Zelber-Sagi S Lotan R Shibolet O Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up Liver Int 2013 33 9 1406 1412 23656177
  • Kong L Zhu J Han W Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study Acta Diabetol 2011 48 1 61 69 20857148
  • Liu Y Gao G Yang C The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus Int J Mol Sci 2014 15 6 10567 10577 24927146
  • Sun LL Jiang BG Li WT Zou JJ Shi YQ Liu ZM MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression Diabetes Res Clin Pract 2011 91 1 94 100 21146880
  • Maschirow L Khalaf K Al-Aubaidy HA Jelinek HF Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes–Biomarkers as a possible tool for early disease detection for rural screening Clin Biochem 2015 48 9 581 585 25753569
  • Arora P Garcia-Bailo B Dastani Z Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes BMC Med Genet 2011 12 95 21756351
  • Donath MY Shoelson SE Type 2 diabetes as an inflammatory disease Nat Rev Immunol 2011 11 2 98 107 21233852
  • Schmidt MI Duncan BB Sharrett AR Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study Lancet 1999 353 9165 1649 1652 10335783
  • Pradhan AD Manson JE Rifai N Buring JE Ridker PM C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 2001 286 3 327 334 11466099
  • Festa A Hanley AJ Tracy RP D’Agostino RJr Haffner SM Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion Circulation 2003 108 15 1822 1830 14517163
  • van Woudenbergh GJ Kuijsten A Sijbrands EJ Hofman A Witteman JC Feskens EJ Glycemic index and glycemic load and their association with C-reactive protein and incident type 2 diabetes J Nutr Metab 2011 2011 623076 21804937
  • Grossmann V Schmitt VH Zeller T Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes Diabetes Care 2015 38 7 1356 1364 25877811
  • Dehghan A Kardys I de Maat MP Genetic variation, C-reactive protein levels, and incidence of diabetes Diabetes 2007 56 3 872 878 17327459
  • Wang Z Shen XH Feng WM Ye GF Qiu W Li B Analysis of inflammatory mediators in prediabetes and newly diagnosed type 2 diabetes patients J Diabetes Res 2016 2016 7965317 27478850
  • Wang X Bao W Liu J Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis Diabetes Care 2013 36 1 166 175 23264288
  • McLaughlin T Abbasi F Lamendola C Differentiation between obesity and insulin resistance in the association with C-reactive protein Circulation 2002 106 23 2908 2912 12460870
  • Madjid M Awan I Willerson JT Casscells SW Leukocyte count and coronary heart disease: implications for risk assessment J Am Coll Cardiol 2004 44 10 1945 1956 15542275
  • Vozarova B Weyer C Lindsay RS Pratley RE Bogardus C Tataranni PA High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes Diabetes 2002 51 2 455 461 11812755
  • Mertoglu C Gunay M Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus Diabetes Metab Syndr Epub 2016 12 12
  • Wang RT Zhang JR Li Y Liu T Yu KJ Neutrophil-Lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes J Diabetes Complications 2015 29 2 245 249 25483847
  • Verdoia M Schaffer A Barbieri L Novara Atherosclerosis Study Group (NAS) Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease Diabetes Metab 2015 41 4 304 311 25656745
  • Demirtas L Degirmenci H Akbas EM Association of hematological indicies with diabetes, impaired glucose regulation and micro-vascular complications of diabetes Int J Clin Exp Med 2015 8 7 11420 11427 26379958
  • Bardini G Dicembrini I Cresci B Rotella CM Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels Diabetes Care 2010 33 2 411 413 19918010
  • Fiorentino TV Hribal ML Perticone M Unfavorable inflammatory profile in adults at risk of type 2 diabetes identified by hemoglobin A1c levels according to the American Diabetes Association criteria Acta Diabetol 2015 52 2 349 356 25246028
  • Festa A D’Agostino RJr Tracy RP Haffner SM Insulin Resistance Atherosclerosis Study Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study Diabetes 2002 51 4 1131 1137 11916936
  • Festa A D’Agostino RJr Mykkänen L Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS) Arterioscler Thromb Vasc Biol 1999 19 3 562 568 10073958
  • Thorand B Kolb H Baumert J Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MON-ICA/KORA Augsburg Study, 1984–2002 Diabetes 2005 54 10 2932 2938 16186395
  • Donath MY Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes Endocrinology 2011 152 11 4005 4006 22021196
  • Carstensen M Herder C Kivimäki M Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study Diabetes 2010 59 5 1222 1227 20185814
  • Bergman M Jagannathan R Buysschaert M Reducing the prevalence of dysglycemia: is the time ripe to test the effectiveness of intervention in high-risk individuals with elevated 1 h post-load glucose levels? Endocrine 2017 55 3 697 701 28124259
  • Bergman M The Early Diabetes Intervention Program--is early actually late? Diabetes Metab Res Rev 2014 30 8 654 658 25400067
  • Bueno AC Sun K Martins CS A novel ADIPOQ mutation (p.M40K) impairs assembly of high-molecular-weight adiponectin and is associated with early-onset obesity and metabolic syndrome J Clin Endocrinol Metab 2014 99 4 E683 E693 24432991
  • Aekplakorn W Tantayotai V Numsangkul S Detecting Pre-diabetes and Diabetes: Agreement between Fasting Plasma Glucose and Oral Glucose Tolerance Test in Thai Adults J Diabetes Res 2015 2015 396505 26347060
  • Gall WE Beebe K Lawton KA alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population PLoS One 2010 5 5 e10883 20526369
  • Suzuki T Imai J Yamada T Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway Diabetes 2011 60 2 537 547 21270264
  • Kim JH Bachmann RA Chen J Interleukin-6 and insulin resistance Vitam Horm 2009 80 613 633 19251052